• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
LeadershipDavos

Biden Pledges Faster U.S. Approval for Cancer Drug Cocktails

By
Reuters
Reuters
Down Arrow Button Icon
By
Reuters
Reuters
Down Arrow Button Icon
January 19, 2016, 1:50 PM ET
Preparations For The World Economic Forum (WEF) 2016
U.S. Vice President Joseph "Joe" Biden speaks during a panel session on cancer research, treatment and data science in Davos, Switzerland, on Tuesday, Jan. 19, 2016. World leaders, influential executives, bankers and policy makers attend the 46th annual meeting of the World Economic Forum in Davos from Jan. 20 - 23. Photographer: Jason Alden/Bloomberg *** Local Caption *** Joe BidenJason Alden—Bloomberg via Getty Images

DAVOS, Switzerland, Jan 19 (Reuters) – U.S. Vice President Joe Biden said on Tuesday that the United States would speed up the approval of promising new drug combinations in his government’s newly announced drive to cure cancer “once and for all.”

Biden, who lost his 46-year-old son Beau to brain cancer last year, set out his plans at a World Economic Forum meeting of international cancer experts in Davos, a week after being appointed to lead the initiative by President Barack Obama.

So-called combination therapy is increasingly seen as central to fighting tumors, as scientists unlock the different genetic factors driving cancer cell growth, but bringing such cocktails to market can be a slow and costly.

Biden said he had hosted a meeting at his home with three unnamed large drug companies and the head of the U.S. Food and Drug Administration (FDA) at which both sides had pledged to do more to get novel cancer drug cocktails to patients.

“The head of the FDA made a commitment that everybody would move much more rapidly in approving combinations,” Biden said.

At the same, the pharmaceutical industry executives had all said they were “open to different way of doing business” in order to ensure that promising drugs from different companies were tested together as early as possible, he added.

Cancer experts are particularly excited by the promise of new immunotherapy medicines that help the body’s immune system fight tumors and which have been shown to work well when used alongside other drugs.

Francis Collins, director of the U.S. National Institutes of Health, described their potential as “breath-taking.”

But such immunotherapy drugs are expensive – typically costing well over $100,000 a year per patient – and companies have traditionally been defensive about sharing early-stage medical experiments.

Obama’s call to “make America the country that cures cancer once and for all” in the last State of the Union address of his presidency has led to criticism from some scientists of an over-simplified approach to the killer condition.

The latest government-led initiative has echoes of former President Richard Nixon’s unsuccessful “War on Cancer” in the 1970s, since when scientists have discovered that cancer is hundreds of different diseases rather than one single disorder, making the notion of a single cure outdated.

Biden acknowledged the complexity in Davos.

“I’m not naive enough to think or suggest we are going to have a cure for every cancer in the world in the near term,” he said.

About the Author
By Reuters
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.